I’m going out on a limb and predicting that IDIX’s nuke will not make it to market and that a tepid 2-DAA regimen for GT1/GT4 is all MRK will be able to show for its efforts in HCV. All told, what % market share do you predict MRK will get US and ex US for it's 2-DAA?